Compare ADMA Biologics Inc (ADMA) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Gilead Sciences, Inc. — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Gilead Sciences, Inc. trades at $135.39 (market cap $169.30B). The key difference: Gilead Sciences, Inc. is far larger — about 79.5× ADMA Biologics Inc's market cap, and Gilead Sciences, Inc. pays a 2.41% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GILD | |
|---|---|---|
Market Cap | $2.13B | $169.30B |
Sector | Health | Health |
52-Week High | $20.38 | $155.80 |
52-Week Low | $7.60 | $108.22 |
Enterprise Value | $2.20B | $183.83B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Gilead Sciences (GILD) trades at $136.36, up 3.88% today and 25.2% over the past year, showing strong momentum. The stock exhibits bullish technical signals with support at $128 and resistance at $136. Fundamentally, GILD maintains robust profitability with a 30.99% net margin and has beaten earnings estimates for three consecutive quarters. Recent FDA and EC approvals for Trodelvy's expanded use in metastatic triple-negative breast cancer provide significant growth catalysts.
GILD presents a compelling investment case with strong analyst support (65.5% buy ratings) and a $156.14 consensus price target offering 14.5% upside. Key risks include generic competition for dolutegravir and execution challenges in oncology growth. The company's solid cash flow generation and expanding product portfolio support continued shareholder value creation despite recent negative net cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
